{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.0","upperLimit":"49.1","value":"34.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"title":"Pre-surgery"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.7","upperLimit":"64.2","value":"48.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"title":"Post-surgery"}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"Highest grade toxicity per subject was counted. Toxicities were graded using Common Toxicity Criteria (CTC) v 2.0. Grade refers to the severity of the toxicity, using Grades 1 through 5 with unique clinical descriptions of severity for a given toxicity based on this general guideline: Grade 1 Mild, Grade 2 Moderate, Grade 3 Severe, Grade 4 Life-threatening or disabling, Grade 5 Death related to toxicity.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oral imatinib mesylate once daily. Treatment continues for 8 weeks in the absence of disease progression. Patients with disease progression are considered for immediate surgical resection. Otherwise, after 8 weeks, patients undergo surgical resection to debulk all gross tumor. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for 2 years.","id":"OG000","title":"Imatinib Mesylate"}],"paramType":"NUMBER","populationDescription":"All eligible patients who started study treatment (for pre-surgery), and who additionally had surgery (post-surgery)","reportingStatus":"POSTED","timeFrame":"Analysis occurs after all patients have been on study for at least 2 years. Measured from start of treatment to end of follow-up, to a maximum of 4.95 years.","title":"Percentage of Patients With Major Toxicity (Toxicity Grade ≥ 3)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}